SENL 103
Alternative Names: S-103; SENL-103Latest Information Update: 28 May 2025
At a glance
- Originator Hebei Senlang Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Multiple myeloma
Most Recent Events
- 28 May 2025 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-myeloma(Second-line therapy or greater) in China (Parenteral, Infusion)
- 06 May 2025 Hebei Senlang Biotechnology plans phase-I trial for Myasthenia gravis (Treatment-experienced, In adults, In the elderly) in China (Parenteral), (NCT06958939)
- 09 Dec 2023 Updated efficacy and adverse events data from a clinical trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)